The treatment groups were well matched demographically ( Table I). A total of 270 patients (of 774 recruited) were randomized as follows: rosuvastatin monotherapy (n=46), ER niacin monotherapy (n=72), ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) today announced results of the LUNAR (Limiting UNdertreatment of Lipids in Acute Coronary Syndrome with Rosuvastatin) study, which showed ...
AstraZeneca today announced the launch of a new clinical trial, SATURN, designed to measure the impact of CRESTOR™ (rosuvastatin) 40 mg and atorvastatin (Lipitor®) 80 mg on the progression of ...
Crestor rosuvastatin calcium is a statin drug, that works by slowing the production of cholesterol by the body, used to lower cholesterol and fats triglycerides in the blood and is used to reduce the ...
NEW ORLEANS — Rosuvastatin 40 mg treatment over a two-year period slowed progression of maximum carotid intima-media thickness among middle-aged adults with a low Framingham risk and evidence of early ...
Kyoto, Japan, Monday 29 September 2003. New data presented at the XIIIth International Symposium on Atherosclerosis (ISA) show AstraZeneca's highly effective statin CRESTOR (rosuvastatin) achieves ...
Government of Newfoundland and Labrador. Strength This refers to the amount of the active medicinal ingredient e. Benefit Status Open - Drugs which are reimbursed with no criteria or prior approval.
On-Admission High-Dose Rosuvastatin Prevents Contrast-Induced Nephropathy in Acute Coronary Syndrome
SAN FRANCISCO, CA—Statin-naïve patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) scheduled for early invasive procedures who receive high-dose rosuvastatin on admission have a ...
The results of 2 studies presented at the 2006 symposium of the International Society of Atherosclerosis in Rome, Italy, have demonstrated the benefit of adding the cholesterol absorption inhibitor ...
A 76-year-old Filipina woman who had been taking rosuvastatin 40 mg per day without a problem for more than 5 years started developing pain and weakness in her thighs just days after starting on the ...
LONDON, January 15 /PRNewswire/ -- AstraZeneca (LSE: AZN) (NYSE: AZN) today announced the launch of a new clinical trial, SATURN, designed to measure the impact of CRESTOR(TM) (rosuvastatin) 40 mg and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback